JP2010519205A5 - - Google Patents

Download PDF

Info

Publication number
JP2010519205A5
JP2010519205A5 JP2009549627A JP2009549627A JP2010519205A5 JP 2010519205 A5 JP2010519205 A5 JP 2010519205A5 JP 2009549627 A JP2009549627 A JP 2009549627A JP 2009549627 A JP2009549627 A JP 2009549627A JP 2010519205 A5 JP2010519205 A5 JP 2010519205A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
dose
cell
immunogenic
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009549627A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519205A (ja
JP5755839B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/002044 external-priority patent/WO2008100598A2/en
Publication of JP2010519205A publication Critical patent/JP2010519205A/ja
Publication of JP2010519205A5 publication Critical patent/JP2010519205A5/ja
Application granted granted Critical
Publication of JP5755839B2 publication Critical patent/JP5755839B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009549627A 2007-02-15 2008-02-15 Ｔ細胞応答の増強方法 Expired - Fee Related JP5755839B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90198007P 2007-02-15 2007-02-15
US60/901,980 2007-02-15
PCT/US2008/002044 WO2008100598A2 (en) 2007-02-15 2008-02-15 A method for enhancing t cell response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013242826A Division JP2014043459A (ja) 2007-02-15 2013-11-25 Ｔ細胞応答の増強方法

Publications (3)

Publication Number Publication Date
JP2010519205A JP2010519205A (ja) 2010-06-03
JP2010519205A5 true JP2010519205A5 (enExample) 2011-03-31
JP5755839B2 JP5755839B2 (ja) 2015-07-29

Family

ID=39690701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009549627A Expired - Fee Related JP5755839B2 (ja) 2007-02-15 2008-02-15 Ｔ細胞応答の増強方法
JP2013242826A Pending JP2014043459A (ja) 2007-02-15 2013-11-25 Ｔ細胞応答の増強方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013242826A Pending JP2014043459A (ja) 2007-02-15 2013-11-25 Ｔ細胞応答の増強方法

Country Status (9)

Country Link
US (1) US20080199485A1 (enExample)
EP (2) EP2129389B1 (enExample)
JP (2) JP5755839B2 (enExample)
CN (2) CN101657213B (enExample)
AU (1) AU2008216669B2 (enExample)
CA (1) CA2678353A1 (enExample)
ES (1) ES2527412T3 (enExample)
MX (1) MX2009008620A (enExample)
WO (1) WO2008100598A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
BRPI0611794A2 (pt) 2005-06-17 2010-09-28 Mannkind Corp métodos e composições para induzir respostas imunes multivalentes contra epìtopos dominantes e subdominantes, expressos em células de cáncer e estroma tumoral
WO2008121354A1 (en) 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
US8728465B2 (en) 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
DE102008061522A1 (de) * 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
WO2010075525A1 (en) * 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Method of using tumor cell debris to reduce brain tumor recurrence or growth
IN2012DN02345A (enExample) 2009-09-16 2015-08-21 Univ Duke
JP2013508415A (ja) 2009-10-23 2013-03-07 マンカインド コーポレイション 癌の免疫療法、および治療の方法
WO2011097573A2 (en) * 2010-02-05 2011-08-11 Mount Sinai School Of Medicine Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
EP3640375A3 (en) 2012-12-11 2020-07-29 Albert Einstein College of Medicine Methods for high throughput receptor/ligand identification
US20150037374A1 (en) * 2013-07-31 2015-02-05 Csl Limited Anti-tumor compositions and uses thereof
US10066323B2 (en) 2014-04-16 2018-09-04 Duke University Electrospun cationic nanofibers and methods of making and using the same
CN107530341B (zh) 2015-03-06 2021-10-01 大连万春布林医药有限公司 治疗与ras突变相关的癌症的方法
WO2016180467A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
EA201792501A1 (ru) 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
DK3334726T3 (da) 2015-07-13 2022-05-16 Beyondspring Pharmaceuticals Inc Plinabulinsammensætninger
AU2017217426B2 (en) 2016-02-08 2022-12-01 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
CA3043630A1 (en) 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018119422A1 (en) 2016-12-22 2018-06-28 Duke University Polycationic microfibers and methods of using the same
JP7369524B2 (ja) * 2016-12-27 2023-10-26 中外製薬株式会社 被験物質の免疫原性を評価する方法
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
CN110381938A (zh) 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法
CA3054955A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
CA3089226A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN112218883A (zh) 2018-04-26 2021-01-12 艾吉纳斯公司 热休克蛋白结合肽组合物及其使用方法
CN111135310B (zh) * 2019-12-24 2021-05-07 江苏省人民医院（南京医科大学第一附属医院） 一种定制化t细胞表位疫苗的双靶向纳米药、其制备方法及应用
CN116096405A (zh) 2020-05-12 2023-05-09 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN116262779A (zh) * 2021-12-14 2023-06-16 深圳先进技术研究院 一种单细胞筛选鉴定人乳头瘤病毒特异性tcr的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778879A (en) * 1982-04-20 1988-10-18 Sloan-Kettering Institute For Cancer Research Highly purified human interleukin 2 and method
DE4143467C2 (de) * 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DE4423392A1 (de) 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Verfahren zur Identifizierung antigener Peptide
JPH10512155A (ja) 1995-02-28 1998-11-24 マックス−プランク−ゲゼルシャフト ツル フェルデルング デアヴイッセンシャフテン エー．ファウ．ベルリン 癌およびその他の過形成を治療する薬剤
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
CN1221349A (zh) * 1996-06-12 1999-06-30 郭亚军 细胞疫苗、免疫治疗以及它们的制备方法
PT1003548E (pt) 1997-07-10 2006-09-29 Mannkind Corp Dispositivo para a inducao de uma resposta por ctl
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
ATE408690T1 (de) * 1998-03-16 2008-10-15 Alk Abello As Mutiertes rekombinantes allergen
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20030215425A1 (en) 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US20020165176A1 (en) * 2000-05-01 2002-11-07 Haynes Joel R. Nucleic acid immunization
GB0023008D0 (en) * 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
EP2295074A1 (en) * 2001-03-07 2011-03-16 Mannkind Corporation Anti-neovasculature preparations for treating cancer
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP2314712B1 (en) * 2001-11-07 2014-01-08 Mannkind Corporation Expression vectors encoding epitopes of antigens and methods for their design
NZ519363A (en) 2002-06-05 2004-02-27 Agres Ltd A novel drug dosing regimen
MXPA05002455A (es) 2002-09-06 2005-06-03 Mannkind Corp Secuencias de epitopes.
ATE476196T1 (de) 2003-06-17 2010-08-15 Mannkind Corp Zusammensetzung zur auslösung, verbesserung und erhaltung von immunantworten gegen mhc-klasse-i- beschränkte epitope, für prophylaktische oder therapeutische zwecke
ATE546153T1 (de) 2003-06-17 2012-03-15 Mannkind Corp Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen
US6997074B2 (en) 2003-10-30 2006-02-14 Eaton Corporation Prediction of destination gear for progressive shift feature
CA2571168A1 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Mhc i-binding ssx-241-49 variants
EP1773402A2 (en) * 2004-06-17 2007-04-18 Mannkind Corporation Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods
MX2007008010A (es) * 2004-12-29 2007-09-07 Mannkind Corp Metodos para desviar celulas cd4+ en la induccion de una inmuno respuesta.
CA2592968A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
EP2351577A1 (en) * 2004-12-29 2011-08-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
CN101146550B (zh) * 2004-12-29 2013-04-17 曼康公司 免疫原性组合物用于制备引发和增强免疫应答的试剂盒的用途
EP1890724A2 (en) * 2005-05-13 2008-02-27 Oxxon Therapeutics Limited Compositions for inducing an immune response

Similar Documents

Publication Publication Date Title
JP2010519205A5 (enExample)
Kayraklioglu et al. CpG oligonucleotides as vaccine adjuvants
Wu et al. Overview of vaccine adjuvants
Otten et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation
Vasilakos et al. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants
Beran Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients
Johansen et al. Lympho-geographical concepts in vaccine delivery
Tomai et al. TLR7/8 agonists as vaccine adjuvants
Higgins et al. Immunostimulatory DNA as a vaccine adjuvant
Akache et al. Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice
CN114762695A (zh) 具有免疫增强活性的包含寡核苷酸的复合体及其用途
Feng et al. Novel polysaccharide from Radix Cyathulae officinalis Kuan can improve immune response to ovalbumin in mice
MX2011012147A (es) Inmunoterapia de vacuna.
JP2015512866A5 (enExample)
Dong et al. Poria cocos polysaccharide induced Th1-type immune responses to ovalbumin in mice
JP2008000001A (ja) 免疫刺激オリゴヌクレオチドおよびその医薬用途
Xiang et al. Promising particle-based vaccines in cancer therapy
JP6698069B2 (ja) 免疫賦活活性を有するＣｐＧスペーサーオリゴヌクレオチド含有複合体及びその用途
JP2006502228A5 (enExample)
JP2012524793A (ja) 免疫調節性生体分子を組み合わせて送達するためのヒドロゲル
Wang et al. Innate endogenous adjuvants prime to desirable immune responses via mucosal routes
Luo et al. Nanomaterials in tuberculosis DNA vaccine delivery: historical perspective and current landscape
US20080014211A1 (en) Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes
Lee et al. Biodegradable cationic polycarbonates as vaccine adjuvants
CN103861099A (zh) 疫苗佐剂、疫苗组合物与牛樟芝子实体之用途